Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Acadia Pharma (ACAD) Tops Q4 EPS by 5c
February 24, 2021 4:23 PM ESTAcadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.42), $0.05 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $121.01 million versus the consensus estimate of $123.2 million.
Acadia delivered strong financial results in the fourth quarter and full year 2020, driven by... More
